The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.
Deal adds a marketed small molecule and three pipeline agents, although Lilly will share revenue from Viktravi and LOXO-195 with Bayer.
Bladder cancer data disappoint shareholders looking for signs of dose response and differentiation from Valstar.
Sanofi has followed a 2015 deal with an €80m stake, joining Lilly and Pfizer as an investor in Biontech.
The New Year is not yet three days old, but deal-hungry investors looking forward to next week’s JP Morgan conference already have a megamerger on their hands.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
Novartis’s Zolgensma comes out on top versus Biogen’s Spinraza, but neither is deemed cost effective by Icer.